Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

When scientists were finally able to create synthetic proteins and nucleic acids in the lab, gene sequencing and DNA chips quickly followed.

But synthesizing these was child’s play compared with the third category of biopolymers known as carbohydrates, or sugars.

MIT researchers report in the Feb. 2 online edition of Science that they have automated the production of these extremely complex molecules for the first time. In so doing, they have opened the door to a flood of potential new research-and disease treatments.

“We have developed a tool that cuts the time required to make an oligosaccharide (a molecule made up of several simple sugar groups joined in a chain) by a factor of 100,” said Peter H. Seeberger, assistant professor of chemistry at MIT and the paper’s main author.

For the first time, biologically significant structures-ones that are involved in cancers and a whole host of diseases-will be readily available for any researcher to probe, analyze and manipulate. Researchers for the first time will be able to design and synthesize large numbers of different sugars, and test their effect on cells.

Complex Building Blocks

Carbohydrates come in so many three-dimensional shapes, and connect to each other in so many ways, that building even a simple oligosaccharide could involve an astronomical number of possible construction combinations.

The difference in complexity between building a protein and building a sugar is akin to stringing beads versus constructing a 3-D scale model of the cathedral of Notre Dame.

Sugars are so difficult for biologists to purify and chemists to synthesize that researchers have been largely unable to study them closely in the body. “People have not gotten their hands on a good quantity of ‘clean’ carbohydrates” to study, Seeberger said.

That is about to change. Seeberger and MIT graduate students Obadiah J. Plante and Emma R. Palmacci started with a commercially available peptide synthesizer (they found a used one relatively cheap). They modified it to mix, wash and cool a series of sugar-based reagents.

Following a simple sequence of steps that ensure that the sugar bonds form as desired, the substance ends up in a small glass cylinder that bubbles and shakes like a witch’s cauldron at regular intervals while it produces the exactly right chain of molecules.

In about 18 hours, the tabletop machine made a complex chain of 12 sugar units, which would have taken around three months to accomplish by hand.

Working Cell-to-Cell

While carbohydrates have a number of functions, including energy storage and metabolism, Seeberger is most excited about their apparent use as a bioreceptor in cell-to-cell communication.

When two cells come together, it is often the loosely attached carbohydrate protruding from one that interacts with the protein on the other. The carbohydrate moderates the interaction-whether beneficial or lethal-between the two.

The challenging sugar structures that Seeberger’s group is attempting to create with the machine are involved in cancer and other diseases. If researchers know what role a specific carbohydrate played in a disease, they may be able to design a drug that either enhances or halts that role.

Carbo Loading

The long-term goal, Seeberger says, is for a biologist or biochemist to be able to buy some monomers (the building blocks of a chain of sugar molecules), and program a machine that spits out the carbohydrate of choice.

While that reality is probably five to 10 years away, within six months researchers will be able to call in an order for a carbohydrate to Plante, one of the authors of the Science paper, who is starting a company to do just that. “Once the chemistry works, the automation is easy,” said Seeberger.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me